| Karen Massey |
Karen Massey is currently the Chief Operating Officer at argenx SE. Prior to her current position, she held the role of Senior Vice President-Product Development at Genentech, Inc. and was a Principal at Pfizer Inc. Ms. Massey completed her undergraduate degree at The University of Sydney and holds an MBA from The Leonard N Stern School of Business. |
| Peter Ulrichts |
Peter Ulrichts is currently the Chief Scientific Officer at argenx SE. Previously, he worked as a Principal at Fédération catholique romaine neuchâteloise. Dr. Ulrichts has an educational background that includes undergraduate, graduate, and doctorate degrees from Ghent University, as well as an undergraduate degree from Katholieke Universiteit Leuven. |
| Luc Truyen |
Luc Truyen is currently the Chief Medical Officer at argenx SE. Previously, he held positions as the Head of Research & Development at Johnson & Johnson Pharmaceutical Group and as the Chief Marketing Officer & Head of R&D at Janssen Alzheimer Immunotherapy. Dr. Truyen obtained a doctorate degree from the University of Antwerp. |
| Karl Gubitz |
Karl Gubitz is currently the Chief Financial Officer at argenx SE. Previously, he worked as the Vice President-Finance at Pfizer Inc. He completed his undergraduate studies at the University of Pretoria and the University of South Africa. He also holds an MBA from Henley Management College. |
| Tim van Hauwermeiren |
Tim van Hauwermeiren is the founder of argenx SE, a company founded in 2008, where he holds the title of Chief Executive Officer & Executive Director since 2014. He is currently the Chairman at Aelin Therapeutics NV since 2014, an Independent Non-Executive Director at iTeos Therapeutics SA since 2018, and an Independent Director at iTeos Therapeutics, Inc. since 2018. Mr. van Hauwermeiren previously served as an Independent Director at Rayzebio, Inc. from 2023 to 2024, held a Group Head position at Procter & Gamble Co., and was a Senior Manager-Business Development at Ablynx NV. He completed his undergraduate and graduate studies at Ghent University and holds an MBA from Vlerick Leuven Gent Management School. |
| Peter K. M. Verhaeghe |
Peter K. M. Verhaeghe is currently the Chairman at Haretis SA since 2011, the Non-Executive Chairman at argenx SE since 2008, a Director at Czechpak Manufacturing Sro, a Non-Executive Director at miDIAGNOSTICS NV since 2020, a Partner at Vermulst Verhaeghe & Graafsma, the President at Merisant France SAS, and a Member-Management Board at Merisant Company 2 SARL. He previously served as the Chairman at PharmaNeuroBoost NV from 2006 to 2013. He also held positions as a Director at Galapagos NV, Fujirebio Europe NV, Merisant Co., KBC Private Equity Fund Biotech NV, Tibotec Virco NV, Movetis NV, Biocartis SA, and Tools & Dies Engineering NV. Additionally, he was an Assistant Professor at Katholieke Universiteit Leuven from 1981 to 1983. Dr. Verhaeghe obtained his graduate degree from Katholieke Universiteit Leuven in 1981 and graduated from Harvard Law School in 1984. |
| Filip Borgions |
Filip Borgions is currently the Global Head-Technical Operations at argenx SE since 2015. Previously, he worked as a Principal at Thrombogenics, Inc. Dr. Borgions has an undergraduate and doctorate degree from Katholieke Universiteit Leuven. |
